Notably, Day and his team underlined that the use of a novel dual-PI3K/mTOR inhibitor (XL765) in the pituitary cell lines and in the GH3 xenograft tumor model increases the anti-tumoral effect of temozolomide [171]. Here, PIK3CG is linked to neoplasm.